Kavingali Corp Announces Opening of Offices in Casper, Wyoming

Today Kavingali Corp. announced the opening of its new corporate headquarters in Casper Wyoming.

Currently, Kavingali Corp is introducing LOTUS FILMTM a hydrophobic self-cleaning applied thin film that is designed to be applied by spray or roller to glass and metal surfaces. The product was designed to assist in new levels of standards for commercial touch surfaces that offers an alternative to constant chemical cleaning.

Kavingali Corp has two versions of the film one designed for outdoor application that has been tested to remain effective for three to five years. The other interior version is designed to last over one year and can easily be applied to high traffic areas such as doors, elevators, escalators, and other high traffic areas in commercial settings. Both product versions are non- toxic but are not designed for use in food preparation or direct food contact applications. The company is currently researching how the Tungsten Trioxide in the LOTUS FILMTM (patent pending) might use natural light (blue light levels of visible light) and photocatalytic process to neutralize pathogens.

The company also has software and robotics divisions that are focused on efficient patient care and cost-effective treatment. ACRUSTM is a healthcare coding and utilization revenue system. It is designed to automate both the billing, quality of care, and utilization functions that are currently conducted by nursing staff manually. Designed to save typical hospital systems up to 45 percent of current departmental costs and provide significant realtime data to managers. The system employs machine learning software that can migrate and analyze both structured and unstructured (physician notes) and then apply algorithms and industry criteria both to code for billing and recommend placement status for billing. APIs are currently being designed to work with all EHR systems and commercial payer systems.

The company is focused on local hire and reutilizing displaced oilfield and gas workers to transition to high tech manufacturing to include custom robotic fingers, thin film coatings, and custom prototyping medical devices. Kavingali, Corp. has several products planned to be made locally and have the label “Made in Casper” and “Made in the USA”. In addition, the company also has patents pending for a 400-450 nm light device for the neutralization of pathogens (viruses) for escalator handrails and for physical therapy/occupational therapy collaborative robots.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”